AbbVie’s AQUIPTA[®]▼ (atogepant) Is Now Available In Scotland For The Prevention Of Migraines In Adults
PRESS RELEASE - For UK consumer, medical and trade media only · The Scottish Medicines Consortium (SMC) has accepted AQUIPTA[®] (atogepant), the oral, once-daily calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for restricted use within NHS Scotland.[1] · The decision follows the Medicines and Healthcare products Regulatory Agency (MHRA) granting the marketing authorisation of atogepant in Great Britain on 30[th] August 2023 for the prophylaxis of migraine in adults who have at least four migraine days per month.[2] · Atogepant demonstrated significant reduction